FibroBiologics, Inc. (FBLG) AI Stock Analysis

• Market Cap: $27.17M
• Dividend Yield: N/A
• Average Volume (3M): 547.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 13
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.34
• Shares Outstanding: 41,395,885
• 10 Day Avg. Volume: 502,843
• 30 Day Avg. Volume: 547,186
• PEG Ratio: 0.03
• Price to Book (P/B): 29.14
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.75
• Enterprise Value/Market Cap: 1.06
• Enterprise Value/Revenue: 17.32
• Enterprise Value/Gross Profit: 103.90
• Enterprise Value/Ebitda: -0.61
• 1Y Price Target: $8.00
• Price Target Upside: 1130.77% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 38 Underperform
• Price Target: ―

FibroBiologics, Inc. is in a challenging position typical for early-stage biotech firms. The company's financials indicate ongoing losses and reliance on external financing, which is a major risk factor. Technical indicators suggest slight momentum but also highlight resistance levels due to its price position below key moving averages. The valuation reflects the unprofitable nature of the firm with no dividend to attract income-focused investors. These factors combined result in a low stock score, emphasizing the company's need for a clear path to revenue generation.

Positive Factors

Clinical Trials

The therapeutic fibroblast platform is positioned to support upcoming clinical trials, having passed required safety testing and being in accordance with cGMP manufacturing protocols.

Expansion Opportunities

The fibroblast pipeline extends beyond current focus in DFU development with plans for Phase 1/2 development in degenerative disc disease and multiple sclerosis.

Market Potential

Chronic wound care represents a sizable market with $28B in healthcare spending with nearly 2 million patients experiencing venous leg ulcers and diabetic foot ulcers annually.

Product Development

FibroBiologic’s drug candidate CYWC628 utilizes its fibroblast spheroid platform and in preclinical studies has demonstrated accelerated wound closure reaching 59% reduction in wound size vs. 35% for Grafix.

Negative Factors

Competitive Landscape

Fibroblast therapy could facilitate improved wound healing quality with superior and timely wound size reduction based on preclinical development.

Regulatory Challenges

The company plans to complete preclinical IND-enabling work for the fibroblast treatment of psoriasis by the end of 2025.

FibroBiologics, Inc. Business Overview & Revenue Model

Company Description

FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

How the Company Makes Money

FibroBiologics, Inc. generates revenue primarily through the development and commercialization of its fibroblast-based therapies. The company may earn income through licensing agreements, partnerships with pharmaceutical companies, and the sale of its therapeutic products once they receive regulatory approval. Additionally, FibroBiologics might secure funding through research grants, equity investments, and collaborations with academic institutions or healthcare organizations. These partnerships and investments support the company's research and development efforts, facilitating the advancement of its innovative therapies to the market.

FibroBiologics, Inc. Financial Statement Overview

Summary

FibroBiologics, Inc. is in a typical pre-revenue biotechnology phase, focusing on R&D with no revenue generation. The financials reveal ongoing losses and dependency on external financing. Despite improvements in equity, the balance sheet shows significant leverage. The company needs to transition towards revenue generation to improve its financial health and achieve sustainability.

Income Statement

FibroBiologics, Inc. has reported no revenue for the past five years, reflecting its pre-revenue stage typical for many biotech firms. The consistent negative EBIT and net income highlight ongoing operational challenges and high R&D expenses. The lack of revenue growth and positive margins demonstrates the company's struggle to achieve profitability.

Balance Sheet

The company's balance sheet reflects high leverage with a debt-to-equity ratio of 0.51. However, there has been a positive trend in equity from negative to positive territory over the years. Despite this, the equity ratio is low at 16.63%, indicating a reliance on liabilities. The improvement in cash and short-term investments suggests better liquidity management.

Cash Flow

FibroBiologics, Inc. continues to report negative operating and free cash flows, reflecting its investment-heavy model with no revenue generation. The fluctuating and negative free cash flow growth rates highlight cash management challenges. The company relies heavily on financing activities to sustain operations, which could pose risks if external funding becomes constrained.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	554.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	277.00K	-573.00K	-437.00K	-94.00K	0.00	0.00
EBITDA	-12.59M	-13.74M	-15.90M	-4.37M	-1.58M	0.00
Net Income	-13.22M	-11.16M	-16.48M	-5.12M	-1.58M	-1.17M
Balance Sheet
Total Assets	13.91M	16.45M	11.82M	4.82M	468.00K	0.00
Cash, Cash Equivalents and Short-Term Investments	8.85M	13.98M	9.16M	2.27M	407.00K	0.00
Total Debt	10.78M	10.55M	1.75M	7.52M	1.52M	0.00
Total Liabilities	13.05M	13.71M	10.57M	8.82M	1.76M	0.00
Stockholders Equity	860.00K	2.73M	1.25M	-4.00M	-1.29M	0.00
Cash Flow
Free Cash Flow	-15.30M	-12.09M	-6.90M	-4.07M	-1.41M	-1.17M
Operating Cash Flow	-14.94M	-11.90M	-6.40M	-4.07M	-1.41M	-1.17M
Investing Cash Flow	-366.00K	-184.00K	-495.00K	0.00	0.00	0.00
Financing Cash Flow	18.18M	16.91M	13.79M	5.92M	1.82M	1.17M

FibroBiologics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FBLG, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 0.65, below the 50-day MA of 0.73, and below the 200-day MA of 1.52, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 45.08 is Neutral, neither overbought nor oversold. The STOCH value of 43.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FBLG.

FibroBiologics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	56 Neutral	$6.50B	15.33	-28.41%	6.35%	11.10%	-32.94%
CNTB	49 Neutral	$110.70M	―	-58.89%	―	―	―
DYAI	46 Neutral	$30.24M	―	-214.26%	―	20.58%	15.90%
FBLG	38 Underperform	$27.17M	―	-559.73%	―	―	―
OKYO	38 Underperform	$116.59M	―	0.00%	―	―	―
FBRX	36 Underperform	$117.37M	―	-130.27%	―	―	43.64%
RVPH	28 Underperform	$29.62M	―	-916.17%	―	―	45.15%

FibroBiologics, Inc. Corporate Events

FibroBiologics Approves Executive Bonuses for 2024

On January 23, 2025, FibroBiologics, Inc. announced that its Compensation Committee and Board of Directors approved the 2024 fiscal year annual incentive bonuses for its executive officers. The updated Summary Compensation Table reveals the total compensation, including bonuses, stock options, and other earnings for the fiscal year ended December 31, 2024. Notably, a bonus of $75,000 was approved for Robert E. Hoffman, the Interim Chief Financial Officer.